$2.33 Million is the total value of Artal Group S.A.'s 105 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CFG | Exit | CITIZENS FINL GROUP INC | $0 | – | -10,000 | -100.0% | -0.01% | – |
| Exit | STERLING CHECK CORP | $0 | – | -25,000 | -100.0% | -0.01% | – | |
| KNTE | Exit | KINNATE BIOPHARMA INC | $0 | – | -125,000 | -100.0% | -0.01% | – |
| BMRN | Exit | BIOMARIN PHARMACEUTICAL INC | $0 | – | -5,028 | -100.0% | -0.01% | – |
| UTHR | Exit | UNITED THERAPEUTICS CORP DEL | $0 | – | -2,971 | -100.0% | -0.02% | – |
| HARP | Exit | HARPOON THERAPEUTICS INC | $0 | – | -1,000,000 | -100.0% | -0.02% | – |
| CRIS | Exit | CURIS INC | $0 | – | -1,300,000 | -100.0% | -0.03% | – |
| CRVS | Exit | CORVUS PHARMACEUTICALS INC | $0 | – | -500,000 | -100.0% | -0.04% | – |
| SANA | Exit | SANA BIOTECHNOLOGY INC | $0 | – | -400,000 | -100.0% | -0.07% | – |
| STOK | Exit | STOKE THERAPEUTICS INC | $0 | – | -250,000 | -100.0% | -0.08% | – |
| CGEM | Exit | CULLINAN ONCOLOGY INC | $0 | – | -250,000 | -100.0% | -0.08% | – |
| Exit | LUCID GROUP INC | $0 | – | -490,000 | -100.0% | -0.10% | – | |
| ALXO | Exit | ALX ONCOLOGY HLDGS INC | $0 | – | -500,000 | -100.0% | -0.12% | – |
| Exit | PORTAGE FINTECH ACQUISITN CO | $0 | – | -380,000 | -100.0% | -0.12% | – | |
| MORF | Exit | MORPHIC HLDG INCcall | $0 | – | -100,000 | -100.0% | -0.18% | – |
| ARAV | Exit | ARAVIVE INC | $0 | – | -4,572,515 | -100.0% | -0.18% | – |
| MRSN | Exit | MERSANA THERAPEUTICS INC | $0 | – | -3,029,555 | -100.0% | -0.31% | – |
| DHR | Exit | DANAHER CORPORATION | $0 | – | -47,500 | -100.0% | -0.35% | – |
| AMAM | Exit | AMBRX BIOPHARMA INCsponsored ads | $0 | – | -702,291 | -100.0% | -0.36% | – |
| PTGX | Exit | PROTAGONIST THERAPEUTICS INC | $0 | – | -500,000 | -100.0% | -0.43% | – |
| RLAY | Exit | RELAY THERAPEUTICS INC | $0 | – | -1,213,725 | -100.0% | -0.47% | – |
| Exit | MOONLAKE IMMUNOTHERAPEUTICSclass a ord | $0 | – | -400,000 | -100.0% | -0.63% | – | |
| SAGE | Exit | SAGE THERAPEUTICS INC | $0 | – | -500,000 | -100.0% | -0.73% | – |
| KRYS | Exit | KRYSTAL BIOTECH INC | $0 | – | -349,669 | -100.0% | -1.27% | – |
| XBI | Exit | SPDR SER TRcall | $0 | – | -1,000,000 | -100.0% | -2.58% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AGENUS INC | 42 | Q3 2023 | 1.9% |
| IRONWOOD PHARMACEUTICALS INC | 42 | Q3 2023 | 0.3% |
| ALNYLAM PHARMACEUTICALS INC | 37 | Q3 2023 | 5.1% |
| LEXICON PHARMACEUTICALS INC | 34 | Q3 2023 | 20.6% |
| AMICUS THERAPEUTICS INC | 30 | Q3 2023 | 2.7% |
| BEIGENE LTD | 28 | Q3 2023 | 7.4% |
| BK OF AMERICA CORP | 28 | Q1 2021 | 4.3% |
| SAGE THERAPEUTICS INC | 28 | Q2 2023 | 1.9% |
| AGIOS PHARMACEUTICALS INC | 28 | Q2 2020 | 1.1% |
| NEKTAR THERAPEUTICS | 27 | Q2 2020 | 1.3% |
View Artal Group S.A.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| WEIGHT WATCHERS INTERNATIONAL INC | February 13, 2015 | 29,443,300 | 51.9% |
View Artal Group S.A.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-03-25 |
| 4 | 2024-03-13 |
| 4 | 2024-02-29 |
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-13 |
| 4 | 2023-10-16 |
| 13F-HR | 2023-08-11 |
| 4 | 2023-06-22 |
| 3 | 2023-06-15 |
| 4 | 2023-06-05 |
View Artal Group S.A.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.